Skip to main navigation Skip to search Skip to main content

Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-l-phenylalanine in CCS-bearing animal models

  • T. Andoh
  • , T. Fujimoto
  • , T. Sudo
  • , I. Fujita
  • , M. Imabori
  • , H. Moritake
  • , T. Sugimoto
  • , Y. Sakuma
  • , T. Takeuchi
  • , S. Kawabata
  • , M. Kirihata
  • , T. Akisue
  • , K. Yayama
  • , M. Kurosaka
  • , S. Miyatake
  • , Y. Fukumori
  • , H. Ichikawa

Research output: Contribution to journalArticlepeer-review

Abstract

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of 10B (45-74ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of l-BPA-fructose complex (500mg BPA/kg).

Original languageEnglish
Pages (from-to)1721-1724
Number of pages4
JournalApplied Radiation and Isotopes
Volume69
Issue number12
DOIs
Publication statusPublished - 12-2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Radiation

Fingerprint

Dive into the research topics of 'Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-l-phenylalanine in CCS-bearing animal models'. Together they form a unique fingerprint.

Cite this